We have demonstrated that US-PLNB has an excellent molecular diagnostic yield in patients with LUAD (diagnostic accuracy for molecular genotyping: 100%) and a diagnostic yield for PD-L1 evaluation of 100% and 96.3% in adenocarcinoma and squamous cell carcinoma, respectively. This evidence concerns the gene CD274 and squamous cell carcinoma.